Part II: Testicular cancer - management of advanced disease

被引:47
作者
Jones, RH
Vasey, PA
机构
[1] Univ Bristol, Sch Med Sci, Dept Pathol & Microbiol, Canc Res UK Mol Oncol Grp, Bristol BS8 1TD, Avon, England
[2] Univ Glasgow, Western Infirm, Beatson Oncol Ctr, Dept Med Oncol, Glasgow G11 6NT, Lanark, Scotland
[3] Beatson Oncol Ctr, Clin Trials Unit, Glasgow, Lanark, Scotland
关键词
D O I
10.1016/S1470-2045(03)01279-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Up to 80% of metastatic germ-cell tumours are curable with conventional chemotherapy. The combination of cisplatin, bleomycin, and etoposide has become the gold standard in this disease. Patients can be divided into good, intermediate, and poor prognosis groups. For those patients with good prognostic features, cure rates reach 90% and attempts have been made to reduce toxic effects of treatment while maintaining efficacy. Patients that relapse require salvage treatment. This can involve the incorporation of drugs such as ifosfamide and taxol into conventional protocols or the use of high-dose chemotherapy with stem-cell transplants. Patients with poor prognosis disease are much more likely to fail conventional chemotherapy and are candidates for dose-intensive protocols or transplants as first-line treatment. Although the results obtained in treating metastatic germ-cell tumours are superior to those with other solid tumour types, there are still many areas that require further improvement.
引用
收藏
页码:738 / 747
页数:10
相关论文
共 80 条
[1]  
BAJORIN DF, 1992, SEMIN ONCOL, V19, P148
[2]   RANDOMIZED TRIAL OF ETOPOSIDE AND CISPLATIN VERSUS ETOPOSIDE AND CARBOPLATIN IN PATIENTS WITH GOOD-RISK GERM-CELL TUMORS - A MULTIINSTITUTIONAL STUDY [J].
BAJORIN, DF ;
SAROSDY, MF ;
PFISTER, DG ;
MAZUMDAR, M ;
MOTZER, RJ ;
SCHER, HI ;
GELLER, NL ;
FAIR, WR ;
HERR, H ;
SOGANI, P ;
SHEINFELD, J ;
RUSSO, P ;
VLAMIS, V ;
CAREY, R ;
VOGELZANG, NJ ;
CRAWFORD, ED ;
BOSL, GJ .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (04) :598-606
[3]   COMPLICATIONS OF POSTCHEMOTHERAPY RETROPERITONEAL LYMPH-NODE DISSECTION [J].
BANIEL, J ;
FOSTER, RS ;
ROWLAND, RG ;
BIHRLE, R ;
DONOHUE, JP .
JOURNAL OF UROLOGY, 1995, 153 (03) :976-980
[4]   High-dose chemotherapy as salvage treatment in germ cell tumors: A Multivariate analysis of prognostic variables [J].
Beyer, J ;
Kramar, A ;
Mandanas, R ;
Linkesch, W ;
Greinix, A ;
Droz, JP ;
Pico, JL ;
Diehl, A ;
Bokemeyer, C ;
Schmoll, HJ ;
Nichols, CR ;
Einhorn, LH ;
Siegert, W .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) :2638-2645
[5]   High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer [J].
Bhatia, S ;
Abonour, R ;
Porcu, P ;
Seshadri, R ;
Nichols, CR ;
Cornetta, K ;
Einhorn, LH .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (19) :3346-3351
[6]   PROGNOSTIC FACTORS FOR FAVORABLE OUTCOME IN DISSEMINATED GERM-CELL TUMORS [J].
BIRCH, R ;
WILLIAMS, S ;
CONE, A ;
EINHORN, L ;
ROARK, P ;
TURNER, S ;
GRECO, FA .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (03) :400-407
[7]  
Bokemeyer C, 1996, ANN ONCOL, V7, P31
[8]   First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis [J].
Bokemeyer, C ;
Kollmannsberger, C ;
Meisner, C ;
Harstrick, A ;
Beyer, J ;
Metzner, B ;
Hartmann, JT ;
Schmoll, HL ;
Einhorn, L ;
Kanz, L ;
Nichols, C .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3450-3456
[9]   Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer [J].
Bokemeyer, C ;
Gerl, A ;
Schöffski, P ;
Harstrick, A ;
Niederle, N ;
Beyer, J ;
Casper, J ;
Schmoll, HJ ;
Kanz, L .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) :512-516
[10]  
BOKEMEYER C, 2003, P AM SOC CLIN ONCOL, V22